VKTX
Viking Therapeutics, Inc.Company with tickers: VKTX
CIK
1607678
CUSIP
92686J106
Shares Outstanding
116,105,643
13F Activity (30d)
205 filings
204 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $0 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $164,125,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Research & Development | $150,150,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Operating Income | $-164,125,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Net Income | $-158,325,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Basic) | $-1.37 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Diluted) | $-1.37 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |